| scholarly article | Q13442814 |
| P50 | author | Steven Rosenberg | Q2347448 |
| P2093 | author name string | David J Munroe | |
| Thomas Ried | |||
| Paul F Robbins | |||
| Cynthia E Dunbar | |||
| Kenneth Cornetta | |||
| Claudia Stewart | |||
| Richard A Morgan | |||
| Zhili Zheng | |||
| Peter D Peng | |||
| Juhua Zhou | |||
| Cyrille J Cohen | |||
| Danny Wangsa | |||
| Cary Hsu | |||
| Xinglei Shen | |||
| Stephanie A Jones | |||
| Keith Kerstann | |||
| Theotonius J Gomes | |||
| P2860 | cites work | Multicolor Spectral Karyotyping of Human Chromosomes | Q22065566 |
| Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma | Q24548019 | ||
| Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells | Q24796392 | ||
| Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences | Q24798872 | ||
| COOH-terminal-modified interleukin-3 is retained intracellularly and stimulates autocrine growth. | Q38343544 | ||
| Capture of antigen-specific T lymphocytes from human blood by selective immortalization to establish long-term T-cell lines maintaining primary cell characteristics | Q40323954 | ||
| Divergent telomerase and CD28 expression patterns in human CD4 and CD8 T cells following repeated encounters with the same antigenic stimulus | Q40683550 | ||
| Ectopic human telomerase catalytic subunit expression maintains telomere length but is not sufficient for CD8+ T lymphocyte immortalization | Q40846658 | ||
| Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a simian immunodeficiency virus-based lentiviral vector system | Q45674295 | ||
| Virus-induced CD8+ T cell clonal expansion is associated with telomerase up-regulation and telomere length preservation: a mechanism for rescue from replicative senescence | Q45750058 | ||
| Polyclonal long-term repopulating stem cell clones in a primate model | Q45855127 | ||
| Gene therapy insertional mutagenesis insights | Q45871758 | ||
| Insertion of retroviral vectors in NOD/SCID repopulating human peripheral blood progenitor cells occurs preferentially in the vicinity of transcription start regions and in introns | Q45879077 | ||
| Retroviral transduction of human peripheral blood lymphocytes with Bcl-X(L) promotes in vitro lymphocyte survival in pro-apoptotic conditions | Q45885040 | ||
| In vitro cellular aging in T-lymphocyte cultures: analysis of DNA content and cell size | Q47391554 | ||
| Transfer of the human telomerase reverse transcriptase (TERT) gene into T lymphocytes results in extension of replicative potential. | Q52018513 | ||
| Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. | Q54662841 | ||
| Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry. | Q55067752 | ||
| Murine leukemia induced by retroviral gene marking | Q77975543 | ||
| IL-15 activates telomerase and minimizes telomere loss and may preserve the replicative life span of memory CD8+ T cells in vitro | Q81546505 | ||
| Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells | Q27860926 | ||
| LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1 | Q28210584 | ||
| Gene therapy: therapeutic gene causing lymphoma | Q28236795 | ||
| Transcription start regions in the human genome are favored targets for MLV integration | Q29618456 | ||
| Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems | Q33933613 | ||
| Interleukin 15: biology and relevance to human disease | Q34116304 | ||
| Rules for making human tumor cells | Q34159004 | ||
| Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. | Q34314036 | ||
| Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. | Q34334845 | ||
| Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. | Q34508425 | ||
| High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation | Q34657652 | ||
| Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. | Q34657661 | ||
| Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine | Q34657676 | ||
| Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions | Q34669675 | ||
| Focus on acute leukemias | Q34747215 | ||
| Occurrence of leukaemia following gene therapy of X-linked SCID. | Q35166805 | ||
| Gene Therapy Targeting Hematopoietic Cells: Better Not Leave It to Chance | Q35570283 | ||
| Chance or necessity? Insertional mutagenesis in gene therapy and its consequences | Q35637501 | ||
| Acute myeloid leukemia is associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque | Q35848273 | ||
| Forkhead transcription factors in immunology. | Q36047235 | ||
| Cytogenetic findings in pediatric T-lymphoblastic lymphomas: one institution's experience and a review of the literature | Q36279935 | ||
| Hematopoietic stem cell gene therapy: dead or alive? | Q36282424 | ||
| Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability | Q36286127 | ||
| Survival of the fittest: in vivo selection and stem cell gene therapy | Q36306141 | ||
| Bcl-2 overexpression enhances tumor-specific T-cell survival | Q36327125 | ||
| Regulated expression of telomerase activity in human T lymphocyte development and activation | Q36366852 | ||
| Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. | Q36369031 | ||
| Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. | Q36424249 | ||
| Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis | Q36427380 | ||
| Chromatin structural elements and chromosomal translocations in leukemia | Q36558869 | ||
| Chromosome abnormalities in advanced stage lymphoblastic lymphoma of children and adolescents: a report from CCG-E08. | Q36686740 | ||
| Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity | Q36726945 | ||
| Spectral karyotyping, a 24-colour FISH technique for the identification of chromosomal rearrangements | Q36893995 | ||
| Safety Issues Related to Retroviral-Mediated Gene Transfer in Humans | Q37219609 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 5168-5177 | |
| P577 | publication date | 2007-03-12 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene | |
| P478 | volume | 109 |
| Q48106124 | A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. |
| Q37257207 | Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology |
| Q37008216 | Adoptive cellular immunotherapy for childhood malignancies |
| Q38178359 | Adoptive immunotherapy for cancer or viruses |
| Q37002020 | Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. |
| Q93039755 | Advances and Challenges of CAR T Cells in Clinical Trials |
| Q37110303 | Advances in clinical research in sickle cell disease |
| Q27027803 | Advances in the treatment of metastatic melanoma: adoptive T-cell therapy |
| Q37969631 | Allogeneic cellular and autologous stem cell therapy for sickle cell disease: 'whom, when and how'. |
| Q47565827 | CAR T cell therapy for multiple myeloma: where are we now and where are we headed? |
| Q38199347 | CD28z CARs and armored CARs |
| Q37909894 | Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know. |
| Q36801106 | Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes |
| Q34338927 | Characterization of human T lymphocytes engineered to express interleukin-15 and herpes simplex virus-thymidine kinase |
| Q37469199 | Chimeric antibody receptors (CARs): driving T-cell specificity to enhance anti-tumor immunity |
| Q38171402 | Chimeric antigen receptor modified T cell therapy for B cell malignancies |
| Q38987239 | Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them |
| Q36059585 | Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. |
| Q39200527 | Development of CAR T cells designed to improve antitumor efficacy and safety |
| Q48097217 | Elevated plasma asymmetric dimethylarginine levels in children with beta-thalassemia major may be an early marker for endothelial dysfunction. |
| Q41179125 | Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety |
| Q49962991 | Engineering chimeric antigen receptor-T cells for cancer treatment |
| Q36140986 | Engineering lymphocyte subsets: tools, trials and tribulations |
| Q92059900 | Engineering strategies to overcome the current roadblocks in CAR T cell therapy |
| Q36889204 | Enhancing adoptive T cell immunotherapy with microRNA therapeutics |
| Q89475558 | Enhancing cancer immunotherapy with nanomedicine |
| Q37129671 | Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients |
| Q54245510 | Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy. |
| Q42696988 | Experimental priapism is associated with increased oxidative stress and activation of protein degradation pathways in corporal tissue. |
| Q38544057 | Extending the lifespan and efficacies of immune cells used in adoptive transfer for cancer immunotherapies-A review |
| Q64230023 | Fueling Cancer Immunotherapy With Common Gamma Chain Cytokines |
| Q37965815 | Genetic engineering of T cells for the immunotherapy of haematological malignancies. |
| Q36909362 | Genetic modification of T cells for immunotherapy |
| Q30839014 | Hepatocyte-secreted extracellular vesicles modify blood metabolome and endothelial function by an arginase-dependent mechanism. |
| Q37110809 | Hypoxia-mediated impaired erythrocyte Lands' Cycle is pathogenic for sickle cell disease |
| Q37536195 | IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia |
| Q36005345 | IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity. |
| Q35328354 | Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells |
| Q35580645 | Immortalization of human and rhesus macaque primary antigen-specific T cells by retrovirally transduced telomerase reverse transcriptase |
| Q33731552 | Immunotherapy in acute leukemia |
| Q28068378 | Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination |
| Q33716478 | In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes |
| Q34745695 | Lack of Duffy antigen expression is associated with organ damage in patients with sickle cell disease |
| Q61813271 | Lymphocytes in Cellular Therapy: Functional Regulation of CAR T Cells |
| Q36928580 | Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy |
| Q36945148 | Network model of survival signaling in large granular lymphocyte leukemia |
| Q26741260 | Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors |
| Q49401353 | Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors |
| Q50035774 | Prospects to improve chimeric antigen receptor T-cell therapy for solid tumors |
| Q37867674 | Pulmonary hypertension in children with sickle cell disease. |
| Q34122292 | Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor |
| Q39493084 | Retroviral insertional mutagenesis can contribute to immortalization of mature T lymphocytes |
| Q38068003 | T cell-based gene therapy of cancer |
| Q34170012 | Telomerase and primary T cells: biology and immortalization for adoptive immunotherapy |
| Q37474007 | Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells |
| Q34036213 | The basic principles of chimeric antigen receptor design |
| Q37567637 | The root of many evils: indolent large granular lymphocyte leukaemia and associated disorders |
| Q39839500 | Transfer of Her-2/neu specificity into cytokine-induced killer (CIK) cells with RNA encoding chimeric immune receptor (CIR). |
| Q38094968 | Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. |
| Q37957140 | Use of allogeneic NK cells for cancer immunotherapy. |
Search more.